Cosentyx is a prescription drug that contains secukinumab, which is a human monoclonal antibody that selectively binds to interleukin‐17A (IL‐17A) cytokine, blocking its interaction with the IL‐17 receptor. This drug is used to treat various inflammatory conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis [1].

According to Drugs.com, Cosentyx has been assigned to pregnancy category B by the FDA, which means that animal reproduction studies have failed to demonstrate a risk to the fetus, but there are no adequate and well-controlled studies in pregnant women. However, it should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus [2].

A study published in the British Journal of Dermatology investigated the effect of secukinumab on pregnancy outcomes. The study included 43 pregnancies in 39 women who received secukinumab during pregnancy. The results showed that there were no major congenital malformations or fetal deaths. However, there were four cases of premature birth, two cases of intrauterine growth restriction, and one case of neonatal hypoglycemia. The authors concluded that although the number of pregnancies was small, the data suggests that secukinumab exposure during pregnancy does not appear to be associated with an increased risk of major congenital malformations [3].

In summary, Cosentyx contains secukinumab, which has been assigned to pregnancy category B by the FDA. There are no adequate and well-controlled studies in pregnant women, but animal studies have failed to demonstrate a risk to the fetus. A study investigating the effect of secukinumab on pregnancy outcomes showed no major congenital malformations, but there were some cases of premature birth, intrauterine growth restriction, and neonatal hypoglycemia [1][2][3].

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://www.drugs.com/pregnancy/secukinumab.html
[3] https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.16901